Superluminal Medicines Secures $60M Series B for Obesity Drug
Superluminal Medicines closed an oversubscribed $60 million Series B financing to advance its lead program for rare genetic obesity forms. The company expects to initiate clinical trials by the end of 2026. This funding fuels pipeline expansion and further program development.
Energy & climate policy: Lease, export, , and subsidy shifts move energy equities fast.